RE: RNS1 Jul 2025 07:39
GenIP Secures First UK Academic Clients
GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce that it has broken into the UK academic technology transfer market by securing its first contracts with leading UK-based research institutions.
Following a productive month attending key UK industry events, the Company has been engaged by a prominent university known for its applied research and industry collaboration and a second public research university recognised for its innovation pipeline across engineering, health sciences, and digital technologies.
Building upon recent expansion into Chile and Brazil, GenIP's entry into the UK academic technology transfer market marks a significant milestone for its global growth strategy and demonstrates the Company's growing role as a trusted partner to leading research institutions.
Melissa Cruz, CEO of GenIP, commented:
"Securing our first UK academic clients is a significant milestone for GenIP and a clear signal of growing demand for our AI-powered technology analytics platform. We're proud to support leading research institutions that are actively investing in commercialising their innovation pipeline.
"These engagements come at a time of strong commercial momentum for GenIP. Following our participation in key industry events across the UK and Europe, we've experienced a material increase in inbound interest from both academic and corporate organisations. These new contracts and several other active commercial discussions underscore our traction in markets that value fast, scalable, and high-quality evaluation tools.
"GenIP is scaling rapidly, increasing adoption across universities, corporate R&D teams, and government innovation programmes. Our platform combines generative AI with expert analysis to help clients make faster, more informed decisions about which innovations to pursue.
"With a growing order book and a stable balance sheet heading into H2, we are focused on disciplined execution, expanding recurring revenues, and continuing to deliver long-term value to shareholders."